Y-Mabs Therapeutics's market cap is currently ―. The company's EPS TTM is $-0.49; its P/E ratio is -30.56; Y-Mabs Therapeutics is scheduled to report earnings on May 10, 2024, and the estimated EPS forecast is $-0.14. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 23.36M	$ 20.45M	$ 20.75M	$ 20.25M	-
Gross Profit	$ 21.32M	$ 17.86M	$ 16.10M	$ 18.17M	-
EBIT	$ -793.00K	$ -7.56M	$ -6.12M	$ -6.39M	-
EBITDA	$ -632.00K	-	$ -5.90M	$ -6.21M	-
Net Income Common Stockholders	$ -988.00K	$ -7.84M	$ -6.30M	$ -6.39M	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 78.64M	$ 86.57M	$ 87.91M	$ 92.63M	$ 105.76M
Total Assets	$ 127.87M	$ 128.88M	$ 132.40M	$ 136.93M	$ 141.46M
Total Debt	$ 1.42M	$ 1.62M	$ 1.25M	$ 1.48M	$ 1.77M
Net Debt	$ -77.22M	$ -84.95M	$ -86.66M	$ -91.14M	$ -104.00M
Total Liabilities	$ 26.88M	$ 28.73M	$ 27.71M	$ 29.62M	$ 32.23M
Stockholders Equity	$ 100.98M	$ 100.15M	$ 104.68M	$ 107.83M	$ 109.22M
Cash Flow	-
Free Cash Flow	$ -8.04M	-	$ -4.73M	$ -13.12M	-
Operating Cash Flow	$ -8.04M	$ -1.34M	$ -4.73M	$ -13.12M	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	$ 100.00K	-	-	-	-

Currency in USD

Y-Mabs Therapeutics Earnings and Revenue History

Income Statement >

Y-Mabs Therapeutics Debt to Assets

Balance Sheet >

Y-Mabs Therapeutics Cash Flow

Cash Flow >

Y-Mabs Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing